Overview

Single Dose Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters for BAY81-8973 and Advate

Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the pharmacokinetics of BAY81-8973 and Advate after intravenous administration.
Phase:
Phase 1
Details
Lead Sponsor:
Bayer
Treatments:
Factor VIII